EXPERIMENTAL IMMUNOLOGY
Anti-allergic effect of luteolin in mice with allergic asthma and rhinitis
Submission date: 2016-05-13
Final revision date: 2016-06-23
Acceptance date: 2016-06-24
Publication date: 2017-05-08
Cent Eur J Immunol 2017;42(1):24-29
KEYWORDS
ABSTRACT
Aim of the study: We aimed to evaluate the anti-allergic effect of luteolin treatment in mice with allergic asthma and rhinitis.
Material and methods: Thirty-two BALB/c mice (n = 8 for each group) were used. Mice in group A (nonallergic group) were exposed to saline, while those in Group B (allergic group) were exposed to ovalbumin (OVA) intraperitoneal (i.p.) injection and intranasal (i.n.) challenge. Null treatment group (Group C) received sterile saline (150 µl) i.p. injection, 30 minutes before each i.n. challenge. Finally, the treatment group (Group D) received luteolin (0.1 mg/kg) by i.p. injection, 30 minutes before each i.n. challenge. We evaluated the number of inflammatory cells including eosinophils, neutrophils and lymphocytes in bronchoalveolar lavage (BAL) fluid, the titers of IL-4, IL-5 and IL-13 in lung homogenate, and we also evaluated histopathologic findings, including infiltration of inflammatory cells into the pulmonary parenchyma and nasal mucosa.
Results: After the OVA challenge, the number of eosinophils, neutrophils and lymphocytes in BAL fluid was significantly increased in group B, compared to group A (p < 0.001). Mice in group C had no significant difference (p > 0.05). On the other hand, group D showed a significant decrease in all inflammatory cells compared to group B (p < 0.05). Also, group D showed a significant decrease in IL-4, IL-5 and IL-13 in their lung homogenate compared to groups B and C (p < 0.05). Group D also showed a significant decrease in inflammatory cell infiltration after luteolin treatment (p < 0.05).
Conclusion: Luteolin had an anti-allergic effect in a murine model of allergic asthma and rhinitis.
Material and methods: Thirty-two BALB/c mice (n = 8 for each group) were used. Mice in group A (nonallergic group) were exposed to saline, while those in Group B (allergic group) were exposed to ovalbumin (OVA) intraperitoneal (i.p.) injection and intranasal (i.n.) challenge. Null treatment group (Group C) received sterile saline (150 µl) i.p. injection, 30 minutes before each i.n. challenge. Finally, the treatment group (Group D) received luteolin (0.1 mg/kg) by i.p. injection, 30 minutes before each i.n. challenge. We evaluated the number of inflammatory cells including eosinophils, neutrophils and lymphocytes in bronchoalveolar lavage (BAL) fluid, the titers of IL-4, IL-5 and IL-13 in lung homogenate, and we also evaluated histopathologic findings, including infiltration of inflammatory cells into the pulmonary parenchyma and nasal mucosa.
Results: After the OVA challenge, the number of eosinophils, neutrophils and lymphocytes in BAL fluid was significantly increased in group B, compared to group A (p < 0.001). Mice in group C had no significant difference (p > 0.05). On the other hand, group D showed a significant decrease in all inflammatory cells compared to group B (p < 0.05). Also, group D showed a significant decrease in IL-4, IL-5 and IL-13 in their lung homogenate compared to groups B and C (p < 0.05). Group D also showed a significant decrease in inflammatory cell infiltration after luteolin treatment (p < 0.05).
Conclusion: Luteolin had an anti-allergic effect in a murine model of allergic asthma and rhinitis.
REFERENCES (14)
1.
Das M, Ram A, Ghosh B (2003): Luteolin alleviates bronchoconstriction and airway hyperreactivity in ovalbumin sensitized mice. Inflamm Res 52: 101-106.
2.
Kim YH, Yang TY, Park CS, et al. (2012): Anti-IL-33 antibody has a therapeutic effect in a murine model of allergic rhinitis. Allergy 67: 183-190.
3.
Kim YH, Park CS, Lim DH, et al. (2012): Beneficial effect of anti-interleukin-33 on the murine model of allergic inflammation of the lower airway. J Asthma 49: 738-743.
4.
Saito H, Matsumoto K, Denburg AE, et al. (2002): Pathogenesis of murine experimental allergic rhinitis: a study of local and systemic consequences of IL-5 deficiency. J Immunol 168: 3017-3023.
5.
El Gazzar M, El Mezayen R, Marecki JC, et al. (2006): Anti-inflammatory effect of thymoquinone in a mouse model of allergic lung inflammation. Int Immunopharmacol 6: 1135-1142.
6.
Finkelman FD, Urban JF (2001): The other side of the coin: the protective role of the TH2 cytokines. J. Allergy Clin Immunol 107: 772-780.
7.
Seder RA, Paul WE, Davis MM, et al. (1992): The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice. J Exp Med 176: 1091-1098.
8.
Pawankar R, Okuda M, Yssel H, et al. (1997): Nasal mast cells in perennial allergic rhinitics exhibit increased expression of the Fc epsilonRI, CD40L, IL-4, and IL-13, and can induce IgE synthesis in B cells. J Clin Invest 99: 1492-1499.
9.
Dabbagh K, Takeyama K, Lee HM, et al. (1999): IL-4 induces mucin gene expression and goblet cell metaplasia in vitro and in vivo. J Immunol 162: 6233-6237.
10.
Foster PS1, Hogan SP, Ramsay AJ, et al. (1996): Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med 183: 195-201.
11.
Cocks BG, de Waal Malefyt R, Galizzi JP, et al. (1993): IL-13 induces proliferation and differentiation of human B cells activated by the CD40 ligand. Int Immunol 5: 657-663.
12.
Xagorari A, Papapetropoulos A, Mauromatis A, et al. (2001): Luteolin inhibits an endotoxin-stimulated phosphorylation cascade and proinflammatory cytokine production in macrophages. J. Pharmacol Exp Ther 296: 181-187.
13.
Park KY, Lee SH, Min BK, et al. (1999): Inhibitory effect of luteolin 4’-O-glucoside from Kummerowia striata and other flavonoids on interleukin-5 bioactivity. Planta Med 65: 457-459.
14.
Shimoi K, Saka N, Kaji K, et al. (2000): Metabolic fate of luteolin and its functional activity at focal site. BioFactors Oxf Engl 12: 181-186.
Share
RELATED ARTICLE
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
